299 related articles for article (PubMed ID: 12665398)
1. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder.
Wagstaff A; Perry C
CNS Drugs; 2003; 17(4):273-80; discussion 281-3. PubMed ID: 12665398
[TBL] [Abstract][Full Text] [Related]
2. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.
Alphs L; Anand R; Islam MZ; Meltzer HY; Kane JM; Krishnan R; Green AI; Potkin S; Chouinard G; Lindenmayer JP; Kerwin R
Schizophr Bull; 2004; 30(3):577-86. PubMed ID: 15631247
[TBL] [Abstract][Full Text] [Related]
3. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Meltzer HY; Alphs L; Green AI; Altamura AC; Anand R; Bertoldi A; Bourgeois M; Chouinard G; Islam MZ; Kane J; Krishnan R; Lindenmayer JP; Potkin S;
Arch Gen Psychiatry; 2003 Jan; 60(1):82-91. PubMed ID: 12511175
[TBL] [Abstract][Full Text] [Related]
4. [Psychoses, mood, suicidal tendencies and clozapine].
Llorca PM; Lançon C; Reine G
Encephale; 1997; 23(6):431-6. PubMed ID: 9488925
[TBL] [Abstract][Full Text] [Related]
5. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder.
Reid WH; Mason M; Hogan T
Psychiatr Serv; 1998 Aug; 49(8):1029-33. PubMed ID: 9712207
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
[TBL] [Abstract][Full Text] [Related]
7. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study.
Ciapparelli A; Dell'Osso L; Pini S; Chiavacci MC; Fenzi M; Cassano GB
J Clin Psychiatry; 2000 May; 61(5):329-34. PubMed ID: 10847306
[TBL] [Abstract][Full Text] [Related]
8. Risperidone augmentation of clozapine: a critical review.
Kontaxakis VP; Ferentinos PP; Havaki-Kontaxaki BJ; Paplos KG; Pappa DA; Christodoulou GN
Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):350-5. PubMed ID: 16900439
[TBL] [Abstract][Full Text] [Related]
9. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.
Glick ID; Zaninelli R; Hsu C; Young FK; Weiss L; Gunay I; Kumar V
J Clin Psychiatry; 2004 May; 65(5):679-85. PubMed ID: 15163255
[TBL] [Abstract][Full Text] [Related]
10. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
11. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
Potkin SG; Alphs L; Hsu C; Krishnan KR; Anand R; Young FK; Meltzer H; Green A;
Biol Psychiatry; 2003 Aug; 54(4):444-52. PubMed ID: 12915289
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
13. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.
Meltzer HY; Okayli G
Am J Psychiatry; 1995 Feb; 152(2):183-90. PubMed ID: 7840350
[TBL] [Abstract][Full Text] [Related]
14. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
[TBL] [Abstract][Full Text] [Related]
15. Prevention of suicide by clozapine in mental disorders: systematic review.
Masdrakis VG; Baldwin DS
Eur Neuropsychopharmacol; 2023 Apr; 69():4-23. PubMed ID: 36640481
[TBL] [Abstract][Full Text] [Related]
16. Switching clozapine responders to olanzapine.
Littrell KH; Johnson CG; Hilligoss NM; Peabody CD; Littrell SH
J Clin Psychiatry; 2000 Dec; 61(12):912-5. PubMed ID: 11206595
[TBL] [Abstract][Full Text] [Related]
17. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
18. Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients.
Iglesias García C; Iglesias Alonso A; Bobes J
Rev Psiquiatr Salud Ment; 2017; 10(4):192-196. PubMed ID: 28844295
[TBL] [Abstract][Full Text] [Related]
19. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
[TBL] [Abstract][Full Text] [Related]
20. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
Ciapparelli A; Dell'Osso L; Bandettini di Poggio A; Carmassi C; Cecconi D; Fenzi M; Chiavacci MC; Bottai M; Ramacciotti CE; Cassano GB
J Clin Psychiatry; 2003 Apr; 64(4):451-8. PubMed ID: 12716249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
